Emerging treatment strategies for metastatic triple-negative breast cancer

Laura A Huppert; Ozge Gumusay; Hope S Rugo

doi:10.1177/17588359221086916

Emerging treatment strategies for metastatic triple-negative breast cancer

Ther Adv Med Oncol. 2022 Apr 7:14:17588359221086916. doi: 10.1177/17588359221086916. eCollection 2022.

Authors

Laura A Huppert¹, Ozge Gumusay¹, Hope S Rugo²

Affiliations

¹ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
² Director, Breast Oncology and Clinical Trials Education, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St., Box 1710, San Francisco, CA 94115, USA.

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often short and median overall survival is only 12-18 months. Therefore, it is critical to identify novel treatment strategies to improve outcomes for these patients. In this review article, we discuss recent advances in treatment strategies for patients with mTNBC including the use of immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates. For each topic, we summarize important preclinical and clinical data, discuss implications for clinical practice, and highlight future research directions.

Keywords: antibody–drug conjugates; emerging therapies; immunotherapy; metastatic triple-negative breast cancer.

Publication types

Review